Psoriasis is a chronic autoimmune skin disease affecting millions worldwide. It is characterised by excessive epidermal proliferation, leading to scaly, reddened lesions that cause pain, itching, and psychological distress. Despite the availability of therapies, psoriasis remains a significant medical challenge, underscoring the need for safer and more effective treatments.

Natural bioactive molecules, such as 20-hydroxyecdysone (HE), are known for anti-inflammatory, regenerative, and tissue-protective properties, making them additionalpromising agents for the topical treatment of dermatological disorders like psoriasis. However, their clinical use is limited by poor skin penetration and low stability, necessitating the use of advanced delivery systems to enhance efficacy.

This study focused on designing transferosome-based formulations aimed at overcoming HE’s limitations. Transferosomes were prepared using thin-film hydration and probe sonication, with phospholipids and edge activators tailored to HE’s properties. Physicochemical characterisation included particle size distribution, polydispersity index (PDI), and zeta potential, ensuring colloidal stability. The encapsulation efficiency (EE%) of HE was determined chromatographically, confirming its effective loading.

Stability studies conducted over a one-month period under controlled conditions monitored particle size, PDI, and zeta potential. According to the results, the optimised formulations maintained integrity and stability, supporting their suitability for dermatological use.

Overall, this work highlights transferosomes as versatile carriers for natural bioactive compounds. By enhancing dermal penetration and maintaining HE stability, these systems significantly improve therapeutic performance. The study bridges the latest achievements in molecular pharmacology and nanotechnology-based drug delivery systems, encompassing new avenues for the innovative topical treatment of inflammatory skin diseases.

The authors acknowledge the Polish Medical Research Agency for funding the project under Grant No. 2024/ABM/03/KPO/KPOD.07.07-IW.07-0043/24-00, entitled “Research aimed at developing a new, innovative pharmaceutical form for the topical treatment of psoriasis vulgaris”.